Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CBLB | Q13191 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695764 | 0.88 | CBLB (0.42) | FADS1NR1I2SMN1; SMN2CBLBMEN1 | |
| SCHEMBL21348773 | 0.83 | KMT2A (0.56) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL18415349 | 0.80 | MEN1 (0.51) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21348780 | 0.79 | ALDH1A1 (0.57) | AKR1C3NR1I2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9978845 | 0.75 | FADS1 (0.64) | FADS1AKR1C3SMN1; SMN2CBLBCA2 | |
| SCHEMBL2096086 | 0.75 | FADS1 (0.59) | FADS1AKR1C3CA2MEN1KMT2A | |
| SCHEMBL21695725 | 0.75 | SMN1; SMN2 (0.69) | FADS1SMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL7773513 | 0.75 | HPGD (0.68) | FADS1AKR1C3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22699673 | 0.75 | FADS1 (0.59) | FADS1AKR1C3SMN1; SMN2CA2BRAF | |
| SCHEMBL23844177 | 0.74 | FADS1 (0.62) | FADS1SMN1; SMN2CBLBBRAFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | FADS1 4412/4885AKR1C3 2033/4885NR1I2 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.